Fig. 5

Anti-TNF therapy alleviates inflammation and fibrosis in liver and kidney. A Representative images of the gallbladder and the knee joint space of the mice. B Quantification of the volume of the gallbladder. At 4.5 months of age, anti-TNF treatment can significantly reduce gallbladder volume (anti-TNF vs. TNF-Tg, statistics: **p = 0.0022; TNF-Tg vs. WT, statistics: ***p = 0.0002; TNF-Tg vs. WT, statistics: *p = 0.0401, 5.5 months old). C Quantification of the volume of the knee joint space (anti-TNF vs. TNF-Tg, statistics: ***p = 0.0002; TNF-Tg vs. WT, statistics: ****p < 0.0001, 4.5 months old). D Representative images of the liver stained with HE and Masson. E–F Quantification of the area of hepatic inflammation (E) and areas of fibrosis (F). The hepatic inflammatory infiltration of TNF-Tg versus WT at 4.5 months old (statistics: *p = 0.0128) and at 5.5 months old (statistics: *p = 0.0447). G Representative images of the kidney with HE and Masson staining. H–I Quantification of glomerular diameter (H) showed that anti-TNF treatment decreased the glomerular diameter in TNF-Tg mice at 4.5 and 5.5 months old (statistics: **p = 0.0021; *p = 0.0177). I Anti-TNF did not improve the deterioration of fibrosis in the kidney. TNF-Tg versus WT at 4.5 and 5.5 months old (statistics: *p = 0.0335; *p = 0.0316)